Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2023 08:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Therapeutics to Present at Jefferies Healthcare Conference

HAMPTON, N.J., June 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference...
May 31, 2023 08:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies

HAMPTON, N.J., May 31, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 1 study of CDX-585. CDX-585 combines highly...
May 15, 2023 08:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™

HAMPTON, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced preclinical data from CDX-622, the Company’s bispecific antibody with dual targeting of the...
May 04, 2023 16:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update

- Phase 2 CSU enrollment completion expected in Q3 2023 -- Phase 1b CSU study and Phase 1 cholinergic cohort both accepted for oral presentation at EAACI 2023 -- Phase 2 EoE study expected to initiate...
March 29, 2023 09:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

HAMPTON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the H.C. Wainwright Autoimmune &...
February 28, 2023 16:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update

- Phase 1b multi-dose CSU data presented at AAAAI on February 26 - - Phase 2 CSU enrollment completion expected by Q3 2023 - HAMPTON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics,...
February 26, 2023 09:00 ET | Source: Celldex Therapeutics, Inc.

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023

- Rapid, profound and durable responses across multiple dosing groups with favorable safety profile observed—positioning barzolimab as a potential best-in-class addition to a historically limited...
February 16, 2023 16:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

HAMPTON, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Rita Jain, M.D. to the Company’s Board of Directors. “We are pleased...
February 15, 2023 07:00 ET | Source: Celldex Therapeutics, Inc.

Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference

HAMPTON, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chat at the SVB Securities Global Biopharma...
February 03, 2023 07:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023

HAMPTON, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that data from the Company’s Phase 1b multi-dose study of barzolvolimab in chronic...